Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Effekten af en lav-histamin-baseret modificeret middelhavskost ved multipel sklerose (HistaMed-MS)

14. november 2026 opdateret af: Murat Açık, Firat University

Et randomiseret kontrolleret forsøg med en lav-histamin-baseret modificeret middelhavskost ved multipel sklerose: Effekten af kostinterventioner på kliniske fund, plasma-histamin og oxidativ stress

This randomized controlled trial will evaluate the effects of a low histamine-based modified Mediterranean diet in adults with relapsing-remitting multiple sclerosis (RRMS). The study will compare three groups: a low-histamine modified Mediterranean diet, a traditional Mediterranean diet, and a control group without dietary intervention. The main outcomes include clinical measures such as disability status, fatigue, and quality of life, as well as blood markers including plasma histamine, diamine oxidase concentration, total antioxidant capacity, and oxidative stress indicators. The goal is to determine whether reducing dietary histamine within a Mediterranean diet pattern provides additional benefits beyond a traditional Mediterranean diet in improving symptoms and biological markers related to inflammation and oxidative stress in RRMS.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system and a leading cause of neurological disability in young adults. Current immunomodulatory treatments have important side effects and do not fully address symptoms or quality of life, highlighting the need for complementary strategies such as targeted dietary interventions. The Mediterranean diet is one of the most promising patterns because of its anti-inflammatory and antioxidant properties and has been associated with reduced fatigue, improved quality of life, and potential benefits on disability in people with MS. However, some components of the traditional Mediterranean diet, such as certain fish, aged cheeses, fermented products, tomatoes, and citrus fruits, are relatively high in histamine. Histamine is a biogenic amine that may influence neuroinflammation and blood-brain barrier permeability, and diets that lower histamine intake have shown benefits in conditions like migraine and gastrointestinal dysfunction, which are common in MS. This study was designed to explore whether a low histamine-based modified Mediterranean diet can optimize the benefits of the Mediterranean pattern in relapsing-remitting MS (RRMS).

The trial is a three-arm, parallel-group, randomized controlled clinical study in adults with RRMS. Participants are randomly assigned to one of three groups: (1) a low histamine-based modified Mediterranean diet, which maintains the core principles of the Mediterranean pattern while restricting foods known to be high in histamine or to promote histamine release; (2) a traditional Mediterranean diet without specific histamine-related restrictions; or (3) a control group that does not receive a structured dietary intervention. The intervention focuses on high intake of fresh vegetables and fruits, legumes, whole grains, olive oil, and appropriate fish options, while the modified diet group additionally limits aged cheeses, processed meats, fermented foods, vinegar, fish and seafood, and selected vegetables and fruits that are high in histamine. This design allows direct comparison of no diet intervention, a well-established Mediterranean pattern, and a targeted low-histamine modification of that pattern.

Clinical outcomes include disability status assessed by the Expanded Disability Status Scale (EDSS), fatigue measured with the Neurological Fatigue Index for Multiple Sclerosis (NFI-MS), and health-related quality of life evaluated with the Multiple Sclerosis Quality of Life-54 (MSQOL-54) questionnaire. To investigate potential mechanisms, blood biomarkers are measured, including serum total antioxidant capacity, oxidative stress markers (for example malondialdehyde), plasma histamine levels, and plasma concentration of diamine oxidase (DAO), an enzyme that metabolizes histamine. The primary hypotheses are that both Mediterranean diet interventions will improve fatigue, quality of life, and oxidative stress parameters compared with the control group, and that the low histamine-based modified Mediterranean diet will provide the greatest benefits, particularly in reducing plasma histamine, increasing DAO concentration, and alleviating fatigue and disability scores in RRMS. If confirmed, the findings could support a more targeted dietary approach as a complementary medical nutrition therapy for MS and provide a basis for future interventional studies on histamine metabolism, oxidative stress, and diet in this population.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

57

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • Elâzığ
      • Elâzığ, Elâzığ, Tyrkiet (Türkiye), 23119
        • Firat University Hospital, Neurology Clinic

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

19 år til 64 år (Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Age 19 to 64 years.
  • Diagnosis of relapsing-remitting multiple sclerosis (RRMS) according to 2017 McDonald criteria.
  • EDSS score < 4.5.
  • On stable immunomodulatory treatment for at least 6 months.
  • Body mass index (BMI) 18.5-29.9 kg/m².

Exclusion Criteria:

  • Relapse and/or corticosteroid treatment within the last 1 month.
  • Clinically significant metabolic, progressive, or malignant disease.
  • Use of at least 1 g/day fish oil supplementation.
  • Insulin-dependent diabetes mellitus.
  • Participation in another interventional study.
  • Weight loss or gain ≥ 5% in the last 6 months.
  • Following a weight-loss diet in the last 2 months.
  • Use of oral anticoagulant therapy.
  • Presence of eating disorders, alcohol or substance dependence.
  • Pregnancy or breastfeeding.
  • Inability to comply with dietary intervention according to weekly follow-up assessments.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Low Histamine-Based Modified Mediterranean Diet

Participants receive a low histamine-based modified Mediterranean diet with restriction of high-histamine and histamine-releasing foods while preserving core Mediterranean diet principles.

Structured dietary program based on the Mediterranean diet with restriction of high-histamine and histamine-releasing foods (e.g., aged cheeses, processed meats, fish and seafood, fermented products, vinegar, some fruits and vegetables); fish is replaced with poultry.

Aktiv komparator: Traditional Mediterranean Diet

Participants receive a traditional Mediterranean diet without specific histamine-related restrictions.

Structured dietary program following a traditional Mediterranean diet rich in vegetables, fruits, whole grains, legumes, olive oil, and fish, without specific histamine-related restrictions.

Ingen indgriben: Control (Usual Diet)

Participants continue their usual diet and do not receive a structured dietary intervention.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in neurological fatigue (Neurological Fatigue Index for Multiple Sclerosis [NFI-MS] subscale scores; ranges: physical fatigue 0-24, cognitive fatigue 0-12, diurnal sleep 0-18, nocturnal sleep 0-15; higher scores indicate greater fatigue)
Tidsramme: Baseline, week 6 and week 12

Fatigue will be assessed using the Neurological Fatigue Index for Multiple Sclerosis (NFI-MS), a 23-item self-reported questionnaire with four subscales: physical fatigue (8 items), cognitive fatigue (4 items), relief by diurnal sleep or rest (6 items), and abnormal nocturnal sleep and sleepiness (5 items). Items are rated from 0 to 3, each subscale is scored separately (no total score is calculated), and higher scores indicate greater fatigue. The outcome is the change in each subscale score from baseline to week 12 across the three study groups.

Baseline, week 6 and week 12
Change in plasma histamine concentration
Tidsramme: From baseline to 12 weeks

Plasma histamine will be measured in fasting EDTA plasma by competitive ELISA. The outcome is the change in plasma histamine concentration (ng/mL) between baseline and the end of the intervention.

From baseline to 12 weeks
Change in plasma diamine oxidase (DAO) concentration
Tidsramme: From baseline to 12 weeks

Plasma diamine oxidase (DAO), a key enzyme of histamine metabolism, will be measured in fasting EDTA plasma by sandwich ELISA. The outcome is the change in plasma DAO concentration (ng/mL) between baseline and the end of the intervention.

From baseline to 12 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in disability status (Expanded Disability Status Scale [EDSS]; scale range: 0-10; higher scores indicate greater disability)
Tidsramme: From baseline to 12 weeks

Disability will be assessed using the Expanded Disability Status Scale (EDSS). The outcome is the change in EDSS score from baseline to the end of the intervention.

From baseline to 12 weeks
Change in health-related quality of life (Multiple Sclerosis Quality of Life-54 [MSQOL-54]; scale range: 0-100 for subscale and composite scores; higher scores indicate better health-related quality of life)
Tidsramme: From baseline to 12 weeks

Health-related quality of life will be assessed using the MSQOL-54 questionnaire. The outcome is the change in MSQOL-54 scores from baseline to the end of the intervention.

From baseline to 12 weeks
Change in serum total antioxidant capacity
Tidsramme: From baseline to 12 weeks

Serum total antioxidant capacity will be measured to evaluate antioxidant status. The outcome is the change in serum total antioxidant capacity between baseline and the end of the intervention.

From baseline to 12 weeks
Change in oxidative stress markers (e.g., malondialdehyde)
Tidsramme: From baseline to 12 weeks

Oxidative stress will be assessed using markers such as malondialdehyde (MDA). The outcome is the change in oxidative stress markers between baseline and the end of the intervention.

From baseline to 12 weeks

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Efterforskere

  • Ledende efterforsker: Murat Gönen, Prof. Dr., Firat University Faculty of Medicine

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

15. juni 2024

Primær færdiggørelse (Faktiske)

10. marts 2025

Studieafslutning (Faktiske)

10. juni 2025

Datoer for studieregistrering

Først indsendt

22. januar 2026

Først indsendt, der opfyldte QC-kriterier

26. marts 2026

Først opslået (Faktiske)

30. marts 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

14. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • 2023/03-26
  • 223S505 (Anden identifikator: The Scientific and Technological Research Council of Turkey (TÜBİTAK))

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

De-identified individual participant data underlying the results reported in the publication will be shared, together with the data dictionary.

IPD-delingstidsramme

Beginning after publication of the main results.

IPD-delingsadgangskriterier

Available from the corresponding author upon reasonable request, subject to approval by the institutional ethics committee.

IPD-deling Understøttende informationstype

  • ANALYTIC_CODE

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .